Breast Implant Illness: Understanding Symptoms, Diagnosis, and Emerging Research

Breast augmentation remains a prevalent cosmetic surgery, with over 300,000 procedures performed annually in the United States. However, increasing attention is being directed towards a constellation of systemic symptoms reported by some individuals following breast implant surgery, collectively known as Breast Implant Illness (BII). This article provides a comprehensive overview of BII, exploring its symptoms, diagnostic challenges, current research, and treatment options.

What is Breast Implant Illness (BII)?

Breast Implant Illness (BII) is not a formally recognized disease with defined diagnostic criteria. Instead, it describes a cluster of symptoms reported by individuals with breast implants, often beginning after implant placement. BII is sometimes used interchangeably with Autoimmune/inflammatory Syndrome Induced by Adjuvants (ASIA), though both are considered part of the same spectrum of systemic reactions [2].

Common Symptoms of BII

The symptoms associated with BII are diverse and often non-specific, making diagnosis challenging. Common reported symptoms include:

• Fatigue
• Arthralgia (joint pain)
• Myalgia (muscle pain)
• Cognitive dysfunction (brain fog, memory problems)
• Dry eyes and mouth
• Autoimmune-like symptoms

Research indicates that arthralgia and fatigue are frequently reported findings among individuals experiencing BII [1]. Individuals may likewise experience a range of other systemic symptoms, potentially leading to diagnoses of autoimmune or rheumatic diseases at a higher rate compared to those without breast implants [2].

The Role of Silicone and Immune Response

Emerging research suggests a potential link between silicone exposure from breast implants and immune system dysfunction. Silicone can migrate from implants into surrounding tissues through several pathways, including surface erosion, gel bleed, and implant ruptures [3].

Once silicone enters the body, immune cells (macrophages) attempt to remove it, but are unable to fully break it down. This can trigger an ongoing immune response and potentially contribute to autoimmune markers [3]. Studies have shown that even in the absence of visible implant leakage, silicone exposure can still elicit an immune reaction [3].

Diagnosis and Management

Diagnosing BII is challenging due to the lack of specific diagnostic criteria. Currently, diagnosis relies on a patient’s reported symptoms and a thorough medical history, often after other potential causes have been ruled out.

The most frequently reported treatment for BII is explantation – the surgical removal of the breast implants, often including the surrounding capsule (capsulectomy). Studies suggest that between 50% and 98% of patients report symptom improvement following explantation [1]. However, the decision to undergo explantation is complex, considering factors such as cost, potential aesthetic changes, and the uncertain outcome.

Trends in Implant Removal

There has been a significant increase in implant removal surgeries worldwide. The International Society of Aesthetic Plastic Surgery (ISAPS) reported a 46.3% increase in implant removal procedures between 2019 and 2023, with over 335,000 procedures performed in 2023 alone [1]. In Colombia, over 9,400 implant removals were performed in 2023, alongside over 28,000 implant placements [1]. Between 2012 and 2022, the Tecnovigilance Program in Colombia recorded 3,831 adverse events related to breast implants, with 5.4% reported as abnormal physiological responses [1].

Future Directions

Given the increasing awareness of BII and the growing number of affected individuals, further research is crucial to better understand the underlying mechanisms, develop standardized diagnostic criteria, and optimize management strategies. A national consensus document is underway to inform the scientific community, patients, and the public regarding the assessment, management, and follow-up of silicone implant-associated disease.